These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 34181760)

  • 21. Randomized dose-escalation designs for drug combination cancer trials with immunotherapy.
    Mozgunov P; Jaki T; Paoletti X
    J Biopharm Stat; 2019; 29(2):359-377. PubMed ID: 30352007
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.
    Zhang Y; Kutner M; Chen Z
    Biom J; 2021 Oct; 63(7):1476-1492. PubMed ID: 33969525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens.
    Gerard E; Zohar S; Lorenzato C; Ursino M; Riviere MK
    Stat Med; 2021 Oct; 40(23):5096-5114. PubMed ID: 34259343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Escalation with overdose control for phase I drug-combination trials.
    Shi Y; Yin G
    Stat Med; 2013 Nov; 32(25):4400-12. PubMed ID: 23630103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-finding design for phase I clinical trials based on Bayesian stochastic approximation.
    Xu J; Zhang D; Mu R
    BMC Med Res Methodol; 2022 Oct; 22(1):258. PubMed ID: 36183071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TEPI-2 and UBI: designs for optimal immuno-oncology and cell therapy dose finding with toxicity and efficacy.
    Li P; Liu R; Lin J; Ji Y
    J Biopharm Stat; 2020 Nov; 30(6):979-992. PubMed ID: 32951518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model.
    Riviere MK; Yuan Y; Dubois F; Zohar S
    Pharm Stat; 2014; 13(4):247-57. PubMed ID: 24828456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
    Ursino M; Biard L; Chevret S
    Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.
    Muenz DG; Braun TM; Taylor JM
    Clin Trials; 2018 Aug; 15(4):386-397. PubMed ID: 29779418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles.
    Du Y; Yin J; Sargent DJ; Mandrekar SJ
    J Biopharm Stat; 2019; 29(2):271-286. PubMed ID: 30403559
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A nonparametric Bayesian method for dose finding in drug combinations cancer trials.
    Razaee ZS; Cook-Wiens G; Tighiouart M
    Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials.
    Shi H; Cao J; Yuan Y; Lin R
    Stat Med; 2021 May; 40(11):2626-2649. PubMed ID: 33650708
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Introduction of Oncology Dose-Finding Trial Designs].
    Takeda K
    Gan To Kagaku Ryoho; 2022 Apr; 49(4):365-370. PubMed ID: 35444116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. gBOIN-ET: The generalized Bayesian optimal interval design for optimal dose-finding accounting for ordinal graded efficacy and toxicity in early clinical trials.
    Takeda K; Morita S; Taguri M
    Biom J; 2022 Oct; 64(7):1178-1191. PubMed ID: 35561046
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.
    Zhong W; Koopmeiners JS; Carlin BP
    Stat Med; 2012 Dec; 31(29):3885-95. PubMed ID: 22807126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction.
    Pan H; Cheng C; Yuan Y
    Pharm Stat; 2020 Sep; 19(5):561-582. PubMed ID: 32248647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Bayesian dose-finding design for outcomes evaluated with uncertainty.
    Schipper MJ; Yuan Y; Taylor JM; Ten Haken RK; Tsien C; Lawrence TS
    Clin Trials; 2021 Jun; 18(3):279-285. PubMed ID: 33884907
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bayesian optimization design for dose-finding based on toxicity and efficacy outcomes in phase I/II clinical trials.
    Takahashi A; Suzuki T
    Pharm Stat; 2021 May; 20(3):422-439. PubMed ID: 33258282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A semi-mechanistic dose-finding design in oncology using pharmacokinetic/pharmacodynamic modeling.
    Su X; Li Y; Müller P; Hsu CW; Pan H; Do KA
    Pharm Stat; 2022 Nov; 21(6):1149-1166. PubMed ID: 35748220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.
    Jimenez JL; Tighiouart M; Gasparini M
    Biom J; 2019 Mar; 61(2):319-332. PubMed ID: 29808507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.